Advisors Capital Management LLC Has $41.22 Million Stock Position in Bristol Myers Squibb Company $BMY

Advisors Capital Management LLC grew its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 4.8% during the third quarter, Holdings Channel reports. The firm owned 913,980 shares of the biopharmaceutical company’s stock after purchasing an additional 41,867 shares during the period. Advisors Capital Management LLC’s holdings in Bristol Myers Squibb were worth $41,221,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the business. Darwin Wealth Management LLC acquired a new position in shares of Bristol Myers Squibb during the 2nd quarter valued at about $25,000. Harbor Capital Advisors Inc. boosted its position in Bristol Myers Squibb by 107.2% during the third quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 313 shares during the period. Total Investment Management Inc. acquired a new position in Bristol Myers Squibb during the second quarter valued at approximately $38,000. Twin Peaks Wealth Advisors LLC bought a new position in shares of Bristol Myers Squibb in the second quarter valued at approximately $40,000. Finally, Mark Sheptoff Financial Planning LLC boosted its holdings in shares of Bristol Myers Squibb by 233.3% during the 2nd quarter. Mark Sheptoff Financial Planning LLC now owns 1,000 shares of the biopharmaceutical company’s stock worth $46,000 after buying an additional 700 shares during the period. 76.41% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

BMY has been the topic of several recent analyst reports. BMO Capital Markets reiterated a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, November 17th. Guggenheim reiterated a “buy” rating and issued a $72.00 price objective (up from $62.00) on shares of Bristol Myers Squibb in a research note on Friday, February 6th. Bank of America upgraded Bristol Myers Squibb from a “neutral” rating to a “buy” rating and increased their target price for the company from $52.00 to $61.00 in a research note on Monday, December 15th. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Bristol Myers Squibb in a research report on Monday, November 24th. Finally, HSBC reissued a “hold” rating and issued a $53.00 price objective on shares of Bristol Myers Squibb in a research report on Wednesday, December 10th. Eight analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $59.20.

Bristol Myers Squibb Price Performance

Shares of BMY stock opened at $60.28 on Wednesday. The company has a market capitalization of $122.76 billion, a P/E ratio of 17.47, a P/E/G ratio of 0.17 and a beta of 0.29. The company has a current ratio of 1.26, a quick ratio of 1.14 and a debt-to-equity ratio of 2.32. Bristol Myers Squibb Company has a 12 month low of $42.52 and a 12 month high of $63.33. The stock has a 50 day moving average of $55.70 and a two-hundred day moving average of $49.72.

Bristol Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 EPS for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The firm had revenue of $12.50 billion during the quarter, compared to analyst estimates of $12.24 billion. During the same quarter in the previous year, the company posted $1.67 earnings per share. The business’s revenue for the quarter was up 1.3% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, equities analysts expect that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, February 2nd. Stockholders of record on Friday, January 2nd were given a dividend of $0.63 per share. This is an increase from Bristol Myers Squibb’s previous quarterly dividend of $0.62. The ex-dividend date was Friday, January 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.2%. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 73.04%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.